Table of Contents

Overview

CREBBP mutations are highly prevalent in both DLBCL and FL.1 This gene has some recurrent sites of mutations (hotspots), mostly in the HAT domain. The pattern of mutations in DLBCL is distinct from FL with the latter having more HAT domain mutations relative to truncating mutations.2

Experimental Evidence

CREBBP missense mutations often affect the histone acetyltransferase (HAT) domain, crucial for regulating gene expression through chromatin modification, or generate a truncated protein.1 In a transgenic mouse model, CREBBP loss cooperated with BCL2 overexpression to promote B-cell lymphomagenesis.3 Mutations in CREBBP and EP300 affect a common pathway and have been described as mutually exclusive due to some functional redundancy.1,4 Studies using genome-wide CRISPR-Cas9 screens have identified synthetic lethal interactions between CREBBP and EP300, suggesting that targeting one may affect the viability of cells with mutations in the other.5

Relevance tier by entity

Entity Tier Description
MZL 2 relevance in MZL not firmly established6
PMBL 1 high-confidence PMBL/cHL/GZL gene7
DLBCL 1 high-confidence DLBCL gene supported by functional data1
FL 1 high-confidence FL gene supported by functional data1
BL 2 association with BL is tenuous8

Mutation incidence in large patient cohorts (GAMBL reanalysis)

Cannot include /DLBCL_CREBBP.md - does not exist yet

Cannot include /FL_CREBBP.md - does not exist yet

Cannot include /BL_CREBBP.md - does not exist yet

Mutation pattern and selective pressure estimates

Cannot include /dnds_CREBBP.md - does not exist yet

CREBBP Hotspots

Chromosome Coordinate (hg19) ref>alt HGVSp
chr16 3788618 G>A R1446C
chr16 3788617 C>T R1446H
chr16 3788617 C>A R1446L
chr16 3788606 A>T Y1450N
chr16 3788606 A>C Y1450D
chr16 3788605 T>G Y1450S
chr16 3788605 T>C Y1450C
chr16 3788596 A>G I1453T
chr16 3788594 G>T L1454I
chr16 3788593 A>C L1454R
chr16 3786715 A>T L1499Q
chr16 3786715 A>G L1499P
chr16 3786715 A>C L1499R
chr16 3786710 C>A E1501*
chr16 3786707 A>T W1502R
chr16 3786707 A>G W1502R
chr16 3786705 C>T W1502*
chr16 3786705 C>G W1502C
chr16 3786705 C>A W1502C
chr16 3786704 A>T Y1503N
chr16 3786704 A>G Y1503H
chr16 3786704 A>C Y1503D
chr16 3786703 T>G Y1503S
chr16 3786703 T>A Y1503F
chr16 3786691 A>G L1507P

View coding variants in ProteinPaint hg19 or hg38

View all variants in GenomePaint hg19 or hg38

CREBBP Expression

Representative Mutations

BL8

Rating ★ ★ ★ ★ ☆

All Mutations

BL

1093 322 324 515 677 745 851

Cannot include /mermaid_CREBBP.md - does not exist yet

References

1.
Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011 Mar 10;471(7337):189–195. PMCID: PMC3271441
2.
Dreval K, Hilton LK, Cruz M, Shaalan H, Ben-Neriah S, Boyle M, Collinge B, Coyle KM, Duns G, Farinha P, Grande BM, Meissner B, Pararajalingam P, Rushton CK, Slack GW, Wong J, Mungall AJ, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns. Blood. 2023 Aug 10;142(6):561–573. PMCID: PMC10644066
3.
García-Ramírez I, Tadros S, González-Herrero I, Martín-Lorenzo A, Rodríguez-Hernández G, Moore D, Ruiz-Roca L, Blanco O, Alonso-López D, Rivas JDL, Hartert K, Duval R, Klinkebiel D, Bast M, Vose J, Lunning M, Fu K, Greiner T, Rodrigues-Lima F, Jiménez R, Criado FJG, Cenador MBG, Brindle P, Vicente-Dueñas C, Alizadeh A, Sánchez-García I, Green MR. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood. 2017 May 11;129(19):2645–2656. PMCID: PMC5428458
4.
Veazey KJ, Cheng D, Lin K, Villarreal OD, Gao G, Perez-Oquendo M, Van HT, Stratton SA, Green M, Xu H, Lu Y, Bedford MT, Santos MA. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. Leukemia. 2020 Dec;34(12):3269–3285. PMCID: PMC7688486
5.
Nie M, Du L, Ren W, Joung J, Ye X, Shi X, Ciftci S, Liu D, Wu K, Zhang F, Pan-Hammarström Q. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma. Cell Death Dis. 2021 Apr 28;12(5):419. PMCID: PMC8080727
6.
Parry M, Rose-Zerilli MJJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One. 2013;8(12):e83244. PMCID: PMC3862727
7.
Duns G, Viganò E, Ennishi D, Sarkozy C, Hung SS, Chavez E, Takata K, Rushton C, Jiang A, Ben-Neriah S, Woolcock BW, Slack GW, Hsi ED, Craig JW, Hilton LK, Shah SP, Farinha P, Mottok A, Gascoyne RD, Morin RD, Savage KJ, Scott DW, Steidl C. Characterization of DLBCL with a PMBL gene expression signature. Blood. 2021 Jul 15;138(2):136–148.
8.
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WWL, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012 Dec;44(12):1321–1325. PMCID: PMC3674561

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.